Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
Hypophysitis
Immune checkpoint inhibitors
Immune-related endocrinopathies
Immunotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
02
02
2023
accepted:
17
02
2023
medline:
31
7
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are a very promising novel class of immune response-regulating drugs for cancer treatment. Hypophysitis is one of their most common immune-related adverse events, occurring in a significant proportion of patients. Since this is a potentially severe entity, regular hormone monitoring is recommended during treatment to allow for a timely diagnosis and adequate treatment. Identification of clinical signs and symptoms, such as headaches, fatigue, weakness, nausea and dizziness, can also be key for its recognition. Compressive symptoms, such as visual disturbances, are uncommon, as is diabetes insipidus. Imaging findings are usually mild and transient and can easily go unnoticed. However, the presence of pituitary abnormalities in imaging studies should prompt closer monitoring, as these can precede clinical manifestations. The clinical importance of this entity relates mainly to the risk of hormone deficiency, especially ACTH, which occurs in the majority of patients and is rarely reversible, requiring lifelong glucocorticoid replacement therapy.
Identifiants
pubmed: 36869230
doi: 10.1007/s00432-023-04659-5
pii: 10.1007/s00432-023-04659-5
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7925-7932Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172(2):195–204. https://doi.org/10.1530/EJE-14-0845
doi: 10.1530/EJE-14-0845
pubmed: 25416723
Albarel F, Castinetti F, Brue T (2019) Management of endocrine disease: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181(3):R107–R118. https://doi.org/10.1530/EJE-19-0169
doi: 10.1530/EJE-19-0169
pubmed: 31311002
Araujo PB, Coelho MCA, Arruda M, Gadelha MR, Neto LV (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38(11):1159–1166. https://doi.org/10.1007/s40618-015-0301-z
doi: 10.1007/s40618-015-0301-z
pubmed: 25957829
Attia P, Phan GQ, Maker A et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053. https://doi.org/10.1200/JCO.2005.06.205
doi: 10.1200/JCO.2005.06.205
pubmed: 16087944
Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 124(6):1111–1121. https://doi.org/10.1002/cncr.31200
doi: 10.1002/cncr.31200
pubmed: 29313945
Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28(6):593–598. https://doi.org/10.1097/01.cji.0000178913.41256.06
doi: 10.1097/01.cji.0000178913.41256.06
pubmed: 16224277
pmcid: 2154350
Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385
doi: 10.1200/JCO.2017.77.6385
pubmed: 29442540
Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100(6):2171–2180. https://doi.org/10.1210/jc.2015-1218
doi: 10.1210/jc.2015-1218
pubmed: 25844620
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207. https://doi.org/10.1038/nrendo.2016.205
doi: 10.1038/nrendo.2016.205
pubmed: 28106152
pmcid: 5629093
Castinetti F, Albarel F, Archambeaud F et al (2019) French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1–G18. https://doi.org/10.1530/ERC-18-0320
doi: 10.1530/ERC-18-0320
pubmed: 30400055
Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17–65. https://doi.org/10.1210/er.2018-00006
doi: 10.1210/er.2018-00006
pubmed: 30184160
Cooksley T, Knight T, Lindsay D et al (2023) Immune checkpoint inhibitor-mediated hypophysitis: no place like home. Clin Med 23(1):81–84. https://doi.org/10.7861/clinmed.2022-0429
doi: 10.7861/clinmed.2022-0429
Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5(2):88–99. https://doi.org/10.1038/ncpendmet1051
doi: 10.1038/ncpendmet1051
pubmed: 19165221
de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B (2019) A Systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(03):145–156. https://doi.org/10.1055/a-0843-3366
doi: 10.1055/a-0843-3366
pubmed: 30861560
de Sousa SMC, Sheriff N, Tran CH et al (2018) Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 21(3):274–282. https://doi.org/10.1007/s11102-018-0866-6
doi: 10.1007/s11102-018-0866-6
pubmed: 29380110
Esfahani K, Roudaia L, Buhlaiga N, del Rincon SV, Papneja N, Miller WH (2020) A Review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(12):87–97. https://doi.org/10.3747/co.27.5223
doi: 10.3747/co.27.5223
Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92. https://doi.org/10.1007/s11102-015-0671-4
doi: 10.1007/s11102-015-0671-4
pubmed: 26186958
Faje AT, Sullivan R, Lawrence D et al (2014) Ipilimumab-Induced Hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99(11):4078–4085. https://doi.org/10.1210/jc.2014-2306
doi: 10.1210/jc.2014-2306
pubmed: 25078147
Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706–3714. https://doi.org/10.1002/cncr.31629
doi: 10.1002/cncr.31629
pubmed: 29975414
Faje A, Reynolds K, Zubiri L et al (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181(3):211–219. https://doi.org/10.1530/EJE-19-0238
doi: 10.1530/EJE-19-0238
pubmed: 31176301
Fucà G, Galli G, Poggi M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 4(1):000457. https://doi.org/10.1136/ESMOOPEN-2018-000457
doi: 10.1136/ESMOOPEN-2018-000457
Hamnvik OPR, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. JNCI J National Cancer Inst 103(21):1572–1587. https://doi.org/10.1093/jnci/djr373
doi: 10.1093/jnci/djr373
Higham CE, Olsson-Brown A, Carroll P et al (2018) Society For Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1–G7. https://doi.org/10.1530/EC-18-0068
doi: 10.1530/EC-18-0068
pubmed: 29930025
pmcid: 6013692
Hypophysitis FA (2016) Evaluation and Management. Clin Diabetes Endocrinol 2(1):15. https://doi.org/10.1186/s40842-016-0034-8
doi: 10.1186/s40842-016-0034-8
Iravani A, Osman MM, Weppler AM et al (2020) FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging 47(12):2776–2786. https://doi.org/10.1007/s00259-020-04815-w
doi: 10.1007/s00259-020-04815-w
pubmed: 32338306
Iwama S, de Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 Mediates hypophysitis secondary to administration of CTLA-4 Blocking antibody. Sci Transl Med. 6(230):332. https://doi.org/10.1126/scitranslmed.3008002
doi: 10.1126/scitranslmed.3008002
Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (oxf) 85(3):331–339. https://doi.org/10.1111/cen.13063
doi: 10.1111/cen.13063
pubmed: 26998595
Kroemer G, Zitvogel L (2021) Immune checkpoint inhibitors. J Exper Med. https://doi.org/10.1084/jem.20201979
doi: 10.1084/jem.20201979
Kuehn HS, Ouyang W, Lo B et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623–1627. https://doi.org/10.1126/science.1255904
doi: 10.1126/science.1255904
pubmed: 25213377
pmcid: 4371526
Lasocki A, Iravani A, Galligan A (2021) The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. Clin Radiol 76(5):325–332. https://doi.org/10.1016/j.crad.2020.12.028
doi: 10.1016/j.crad.2020.12.028
pubmed: 33593600
Laurent S, Queirolo P, Boero S et al (2013) The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 11(1):108. https://doi.org/10.1186/1479-5876-11-108
doi: 10.1186/1479-5876-11-108
pubmed: 23634660
pmcid: 3663700
Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti–ctla-4 antibody in patients with metastatic melanoma. J Immun 29(4):455–463. https://doi.org/10.1097/01.cji.0000208259.73167.58
doi: 10.1097/01.cji.0000208259.73167.58
Min L, Vaidya A, Becker C (2012) Association of Ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18(3):351–355. https://doi.org/10.4158/EP11273.OR
doi: 10.4158/EP11273.OR
pubmed: 22138079
pmcid: 3997164
Min L, Hodi FS, Giobbie-Hurder A et al (2015) Systemic High-dose corticosteroid treatment does not improve the outcome of Ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21(4):749–755. https://doi.org/10.1158/1078-0432.CCR-14-2353
doi: 10.1158/1078-0432.CCR-14-2353
pubmed: 25538262
Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https://doi.org/10.1038/s41572-020-0160-6
doi: 10.1038/s41572-020-0160-6
pubmed: 32382051
pmcid: 9728094
Romano E, Kusio-Kobialka M, Foukas PG et al (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112(19):6140–6145. https://doi.org/10.1073/pnas.1417320112
doi: 10.1073/pnas.1417320112
pubmed: 25918390
pmcid: 4434760
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690
doi: 10.1056/NEJMoa1200690
pubmed: 22658127
pmcid: 3544539
Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23(2):39. https://doi.org/10.1208/s12248-021-00574-0
doi: 10.1208/s12248-021-00574-0
pubmed: 33677681
U.S. Food and Drug Administration. Dorstalimab. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174 . Accessed 20 Feb 2022.
Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 30(21):2691–2697. https://doi.org/10.1200/JCO.2012.41.6750
doi: 10.1200/JCO.2012.41.6750
pubmed: 22614989
Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389–399. https://doi.org/10.1038/s41574-021-00484-3
doi: 10.1038/s41574-021-00484-3
pubmed: 33875857
pmcid: 8769055